1)日本産科婦人科学会・日本病理学会(編):卵巣腫瘍・卵管癌・腹膜癌取扱い規約,金原出版,2016
2)日本婦人科腫瘍学会(編):卵巣がん治療ガイドライン2015年版,金原出版,2015
3)田中優美子:産婦人科の画像診断,金原出版,2014
4)Satoh T, Aoki Y, Kasamatsu T, et al:Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer 51:340-351,2015
5)Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al:Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303-314,2008
6)Scaletta G, Plotti F, Luvero D, et al:The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther 17:827-839,2017
7)Seidman JD, Kurman RJ, Ronnett BM:Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27:985-993,2003
8)Manabe T, Hirose Y, Kiryuu T, et al:Magnetic resonance imaging of endometrial cancer and clear cell cancer. J Comput Assist Tomogr 31:229-235,2007
9)Kobayashi H:Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol 14:378-382,2009
10)Satoh T, Oki A, Uno K, et al:High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 97:1053-1057,2007
11)Sakurai M, Matsumoto K, Gosho M, et al:Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism. Int J Gynecol Cancer 27:37-43,2017